# Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

Study · id `cardio:ct-nct07232030` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07232030](<https://clinicaltrials.gov/study/NCT07232030>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07232030

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.

## Technical summary

Registry record NCT07232030. Randomized; no masking; primary purpose treatment. Start 2026-04-24 (actual); primary completion 2033-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2500 participants (planned count; ClinicalTrials.gov record NCT07232030, source copy `cardio:ctgov-nct07232030-2026-11-18`, retrieved 2026-11-18)
- Started: 2026-04-24 (actual) (ClinicalTrials.gov record NCT07232030, source copy `cardio:ctgov-nct07232030-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2033-01 (anticipated) (ClinicalTrials.gov record NCT07232030, source copy `cardio:ctgov-nct07232030-2026-11-18`, retrieved 2026-11-18)
- Completion: 2033-01 (anticipated) (ClinicalTrials.gov record NCT07232030, source copy `cardio:ctgov-nct07232030-2026-11-18`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07232030, source copy `cardio:ctgov-nct07232030-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07232030-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
- Acronym: BENEFIT-HF
- Condition: Heart Failure
- Condition: Heart Failure NYHA Class II
- Condition: Heart Failure NYHA Class III
- Intervention (Device): Barostim System
- Intervention (Other): Usual care medical management
- Lead sponsor: CVRx, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 7bbe2af4113ecc9fa2a392dcf3a35d1adec557265e6a28c69ee597b28e8f5304
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
